Zentalis Pharmaceuticals Inc. (ZNTL): Price and Financial Metrics

Zentalis Pharmaceuticals Inc. (ZNTL): $15.76

0.57 (+3.75%)

POWR Rating

Component Grades

Momentum

C

Stability

D

Sentiment

Quality

C

Add ZNTL to Watchlist
Sign Up

Industry: Biotech

Industry

F

Ranked

#197 of 365

in industry

ZNTL Price/Volume Stats

Current price $15.76 52-week high $31.46
Prev. close $15.19 52-week low $9.56
Day low $15.22 Volume 580,000
Day high $16.08 Avg. volume 825,152
50-day MA $13.46 Dividend yield N/A
200-day MA $18.60 Market Cap 1.12B

ZNTL Stock Price Chart Interactive Chart >


Zentalis Pharmaceuticals Inc. (ZNTL) Company Bio


Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on discovering and developing clinically differentiated, novel small molecule therapeutics targeting fundamental biological pathways of cancer. It develops a broad pipeline of product candidates with an initial focus on validated oncology targets with the potential to address large patient populations. Its lead product candidate, ZN-c5, is an oral selective estrogen receptor degrader (SERD) for the treatment of estrogen receptor positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) advanced or metastatic breast cancer. The company was founded by Kevin D. Bunker on December 23, 2014 and is headquartered in New York, NY.


ZNTL Latest News Stream


Event/Time News Detail
Loading, please wait...

ZNTL Latest Social Stream


Loading social stream, please wait...

View Full ZNTL Social Stream

Latest ZNTL News From Around the Web

Below are the latest news stories about ZENTALIS PHARMACEUTICALS INC that investors may wish to consider to help them evaluate ZNTL as an investment opportunity.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) Is In A Good Position To Deliver On Growth Plans

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Yahoo | December 27, 2023

Zentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

NEW YORK and SAN DIEGO, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on December 1, 2023, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 42,000 shares of the Company’s common stock and 28,0

Yahoo | December 1, 2023

David Johnson Bought 16% More Shares In Zentalis Pharmaceuticals

Investors who take an interest in Zentalis Pharmaceuticals, Inc. ( NASDAQ:ZNTL ) should definitely note that the...

Yahoo | November 16, 2023

Director David Johnson's Strategic Purchase of Zentalis Pharmaceuticals Inc Shares

In the realm of stock market movements, insider trading activity is often a significant indicator that investors monitor to gauge the confidence of management and key stakeholders in the company's future.

Yahoo | November 14, 2023

Zentalis to Participate in Investor Call Focused on Ovarian Cancer with Gynecologic Oncology Key Opinion Leader Joyce F. Liu, M.D., MPH, Hosted by TD Cowen

Investor call to be held on Friday, November 10th, at 10:00 a.m. ET Company also to participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 15th, 2023 at 8:30 a.m. GMT NEW YORK and SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, toda

Yahoo | November 9, 2023

Read More 'ZNTL' Stories Here

ZNTL Price Returns

1-mo 1.74%
3-mo 4.03%
6-mo -21.44%
1-year -5.23%
3-year -60.90%
5-year N/A
YTD 4.03%
2023 -24.78%
2022 -76.04%
2021 61.84%
2020 N/A
2019 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!